News

AgroSpheres Novel Encapsulation Platform Now Listed by Organic Materials Review Institute (OMRI) for Use in Organic Crop Production

AgroSpheres, Inc., an agricultural biobased solutions developer, is pleased to announce that its proprietary encapsulation technology, AgroSpheres® Microbially-Derived Minicells (also known as the AgriCell), was recently reviewed by the Organic Materials Review Institute (OMRI), which has determined that it meets the criteria for use under the USDA National Organic Program (NOP). AgroSpheres® Microbially-Derived Minicells is now listed in OMRI’s Generic Material Listing for use as an inert ingredient in organic crop pest, weed, and disease control. This product is currently pending review and approval by US EPA. Once that approval is granted, it will be available for use in pesticide products for use in organic and conventional crop production.

OMRI’s mission is to support the growth and trust of the global organic community through expert, independent and transparent verification of input materials, and through education and technical assistance. OMRI provided an independent review of the AgriCell encapsulation technology and concluded that the AgriCell met the very high standards that NOP has created for the organic industry. This significant milestone marks a major step forward in advancing environmentally friendly and efficient agricultural practices.

“Obtaining OMRI listed status demonstrates that AgroSpheres’ encapsulation technology complies with the rigorous standards set by NOP for organic production, providing farmers with a trusted and reliable solution to enhance crop yields while maintaining the integrity of their organic operations,” said Payam Pourtaheri, Chief Executive Officer for AgroSpheres.

Emily Pelton, who represents the Virginia Wine Board on the National Grape Research Alliance and is the founder of the Virginia Wine Research exchange, said: “The Wine Board are proud to be early supporters of the AgroSpheres team because we are always on the lookout for more environmentally friendly ways of doing things and this is what AgroSpheres is all about. We are examining everything we can to avoid using toxic materials for disease management, from good vineyard management practices to breeding disease resistant grape varieties. Sadly, this is not easy, and we have fewer tools for organic production than we would like. Hence, we are very excited that AgroSpheres is going to bring a new tool to the toolbox to help fight grape vine diseases that are good for the environment.”

The encapsulated products will be sold through various distributors after product approvals.

To see the OMRI Listed® certificate for AgroSpheres® Microbially-Derived Minicells, click here.

Recent News

08/25/2026

United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the FDA has accepted the New Drug Application (NDA) for ralinepag to treat PAH. The FDA has set a Prescription Drug User Fee Act target action date of June 24, 2027. Ralinepag has not been approved for use in any indication by the

08/19/2026

ATCC Receives New CDC Award to Advance Influenza Testing and Surveillance

ATCC has been selected by the Centers for Disease Control and Prevention (CDC) for a new contract to support serological assays for the detection and characterization of influenza viruses. The award, valued at up to $7.3 million over the 5-year contract period (contract 75D30126C21030), will support CDC’s National Center for Immunization and Respiratory Diseases, Influenza

08/18/2026

Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™

Nanochon, a medical device company developing Chondrograft™, a novel patented implant for the treatment of articular cartilage defects of the knee, today announced that it has received regulatory approval from Panamá’s Ministry of Health to initiate its First-in-Human (FIH) clinical study in Panamá. The study will evaluate the safety and performance of Chondrograft™ in patients